<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369732</url>
  </required_header>
  <id_info>
    <org_study_id>3-2011-0086</org_study_id>
    <nct_id>NCT01369732</nct_id>
  </id_info>
  <brief_title>Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest</brief_title>
  <official_title>Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Thoracic Aorta Surgery With Hypothermic Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During thoracic aortic surgery, hypothermic cardiac arrest causes aortic ischemia and
      reperfusion (IR) periods, respectively. Aortic ischemia results in an ischemic insult to the
      lower extremities and successive reperfusion results in injury to remote organs, including
      kidneys. So, there has been considerable interest in the development of therapeutic
      strategies aimed at attenuating IR injury. One such group of agents that are attracting
      interest due to their potential protective effects on vascular endothelium is the
      erythropoietin.

      However, the effect of erythropoietin on renal injury induced by aortic IR in humane has not
      been fully clarified. Therefore, the purpose of this study is to determine whether the
      prophylactic administration of erythropoietin reduce the incidence of acute kidney injury
      (AKI) in patients undergoing thoracic aorta surgery with hypothermic cardiac arrest. The
      investigators administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min
      before the commencement of ischemia. The differences between the control and study groups are
      observed by clinical indicators such as serum creatinine, TNF-Î±, NGAL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Acute Kidney Injury Based on RIFLE Criteria</measure>
    <time_frame>upto 7 days after surgery</time_frame>
    <description>Serum creatinine, GFR, urine output will be measured at 6:00 AM everyday up to 7 days after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Acute Kidney Injury Based on RIFLE Criteria</measure>
    <time_frame>upto 7 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>upto 1 month after surgery</time_frame>
    <description>Participants will be followed for the mortality, an expected average of 1 month after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Duration of Mechanical Ventilation</measure>
    <time_frame>upto 2 weeks after surgery</time_frame>
    <description>Participants will be followed for the duration of mechanical ventilation, an expected average of 2 weeks after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Duration of ICU Stay</measure>
    <time_frame>upto 2 weeks after surgery</time_frame>
    <description>Participants will be followed for the duration of ICU stay, an expected average of 2 weeks after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Duration of Hospital Stay</measure>
    <time_frame>upto 1 month after surgery</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 1 month after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Dissection of Thoracic Aorta</condition>
  <arm_group>
    <arm_group_label>Saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>erythropoietin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human erythropoietin</intervention_name>
    <description>We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.</description>
    <arm_group_label>erythropoietin group</arm_group_label>
    <other_name>epocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.</description>
    <arm_group_label>Saline group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults above age of 20

          2. Undergoing Thoracic Aorta Surgery with Hypothermic Cardiac Arrest

        Exclusion Criteria:

          1. pregnancy or lactation

          2. cerebrovascular thrombosis 3. past history of pulmonary embolism or thrombosis

          3. past history of thoracic aortic surgery

          4. malignancy 5. preoperative acute kidney injury

          5. chronic renal replacement therapy

          6. allergy or hypersensitivity to erythropoetin

          7. history of erythropoetin treatment

          8. death during or one day after surgery

          9. no consent

         10. reoperation within seven days of the first surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yon Hee Shim</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>July 10, 2013</results_first_submitted>
  <results_first_submitted_qc>July 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2013</results_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at the university hospital between May 2011 and January 2013.</recruitment_details>
      <pre_assignment_details>Six patients were dropped out regarding wrong dose-count of erythropoietin (n = 1), death within 24 hours after surgery (n = 2), and screening failure due to chronic kidney disease (n = 3).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Saline Group</title>
          <description>We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.</description>
        </group>
        <group group_id="P2">
          <title>Erythropoietin Group</title>
          <description>We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline Group</title>
          <description>We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.</description>
        </group>
        <group group_id="B2">
          <title>Erythropoietin Group</title>
          <description>We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="12"/>
                    <measurement group_id="B2" value="61" spread="13"/>
                    <measurement group_id="B3" value="63" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Kidney Injury Based on RIFLE Criteria</title>
        <description>Serum creatinine, GFR, urine output will be measured at 6:00 AM everyday up to 7 days after surgery.</description>
        <time_frame>upto 7 days after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>Participants will be followed for the mortality, an expected average of 1 month after surgery.</description>
        <time_frame>upto 1 month after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Duration of Mechanical Ventilation</title>
        <description>Participants will be followed for the duration of mechanical ventilation, an expected average of 2 weeks after surgery.</description>
        <time_frame>upto 2 weeks after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Duration of ICU Stay</title>
        <description>Participants will be followed for the duration of ICU stay, an expected average of 2 weeks after surgery.</description>
        <time_frame>upto 2 weeks after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Duration of Hospital Stay</title>
        <description>Participants will be followed for the duration of hospital stay, an expected average of 1 month after surgery.</description>
        <time_frame>upto 1 month after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Kidney Injury Based on RIFLE Criteria</title>
        <time_frame>upto 7 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Group</title>
            <description>We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.</description>
          </group>
          <group group_id="O2">
            <title>Erythropoietin Group</title>
            <description>We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Kidney Injury Based on RIFLE Criteria</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Saline Group</title>
          <description>We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.</description>
        </group>
        <group group_id="E2">
          <title>Erythropoietin Group</title>
          <description>We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yon Hee Shim</name_or_title>
      <organization>Yonsei University College of Medicine</organization>
      <phone>82220193547</phone>
      <email>tren125@yuhs.ac</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

